AKAP9
AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
Overview
Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus. Required for microtubule nucleation at the cis-side of the Golgi apparatus.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.86, affected pathway 0.89, genetic association 0.41, somatic mutation 0.50). IntOGen calls it a driver in 10 cohorts (5 activating, 4 loss-of-function), covering Basal Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
- 1 · What it is
AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.
- 2 · What goes wrong in cancer
Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus.
- 3 · How drugs use it
No product in this corpus aims at AKAP9 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:379 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q99996 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000127914 (association with cancer (MONDO_0004992) 0.67; (GraphQL API, CC0)); IntOGen AKAP9 (driver in 10 cohorts (Act 5, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Scaffolding protein that assembles several protein kinases and phosphatases on the centrosome and Golgi apparatus. Required to maintain the integrity of the Golgi apparatus. Required for microtubule nucleation at the cis-side of the Golgi apparatus. Required for association of the centrosomes with the poles of the bipolar mitotic spindle during metaphase. In complex with PDE4DIP isoform 13/MMG8/SMYLE, recruits CAMSAP2 to the Golgi apparatus and tethers non-centrosomal minus-end microtubules to the Golgi, an important step for polarised cell movement. In complex with PDE4DIP isoform 13/MMG8/SMYLE, EB1/MAPRE1 and CDK5RAP2, contributes to microtubules nucleation and extension also from the centrosome to the cell periphery. Location: Golgi apparatus; Cytoplasm; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome (UniProt). Locus 7q21.2 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Breast cancer: IntOGen driver in 1 cohort (BRCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"AKAP9" OR ABSTRACT:"AKAP9" OR TITLE:"A-kinase anchoring protein 9" OR ABSTRACT:"A-kinase anchoring protein 9" OR TITLE:"A-kinase anchor protein 9" OR ABSTRACT:"A-kinase anchor protein 9" OR TITLE:"KIAA0803" OR ABSTRACT:"KIAA0803" OR TITLE:"AKAP350" OR ABSTRACT:"AKAP350" OR TITLE:"AKAP450" OR ABSTRACT:"AKAP450") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AKAP9, not a curated reading list.